Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Companyâ€™s lead molecule is named rose bengal sodium (RBS). The Companyâ€™s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Companyâ€™s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	0.0606 $	-11.40%	155,363
11/06/26	0.0684 $	-0.29%	17,000
10/06/26	0.0686 $	+1.78%	51,490
09/06/26	0.0674 $	+6.85%	10,090
08/06/26	0.0631 $	+0.13%	17,000

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Market Closed - OTC Markets Other stock markets 23:05:38 12/06/2026 +04			5-day change	1st Jan Change
0.0606 ^USD	-11.40%		-3.81%	+8.41%

05-18	Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study	RE
05-18	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study	CI

Market Cap	25.47M 22.02M 20.28M 19M 35.63M 2.42B 36.16M 240M 93.52M 1.18B 95.58M 93.54M 4.08B	P/E Ratio 2024	-10.6x	P/E Ratio 2025	-4.33x
Enterprise Value	28.2M 24.38M 22.46M 21.03M 39.44M 2.68B 40.03M 266M 104M 1.3B 106M 104M 4.52B	EV / Sales 2024	86,451,912x	EV / Sales 2025	78,013,766x
Free-Float	92.21%	Yield 2024 *	-	Yield 2025	-

05-18	Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study	RE
05-18	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study	CI
05-14	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Provectus Biopharmaceuticals, Inc. Presents New Data on Rose Bengal Photodynamic Antimicrobial Therapy At Arvo 2026	CI
04-02	Provectus Biopharmaceuticals Highlights Preclinical Evidence Of PV-10-Mediated Immune Modulation In Burn Wound Healing	CI
03-26	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-13	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
09/10/25	Provectus Biopharmaceuticals Positions Pv-10 as Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel Sting-Pathway Activation for Improving Hepatitis B Vaccine Efficacy	CI
29/09/25	Provectus Biopharmaceuticals initiates preclinical study of oral PV-10	RE
29/09/25	Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer	CI
14/08/25	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
17/07/25	Provectus Biopharmaceuticals, Inc. cancelled the transaction announced on July 17, 2024	CI

06-08	Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders	AQ
05-18	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End	AQ
05-14	Provectus: Q1 Earnings Snapshot	AQ
05-04	Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis	AQ
04-21	Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee	AQ

Provectus Biopharmaceuticals, Inc. Stock

Stocks

PVCT

US74373P1084

Biotechnology & Medical Research

Valuation: Provectus Biopharmaceuticals, Inc.

Chart: Provectus Biopharmaceuticals, Inc.

Latest news : Provectus Biopharmaceuticals, Inc.

Last Transcript: Provectus Biopharmaceuticals, Inc.

Press Releases: Provectus Biopharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Provectus Biopharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-11.40%
1 week	-3.81%
Current month	-6.77%
1 month	-13.18%
3 months	+7.45%
6 months	-5.16%
Current year	+8.41%

1 week	0.06	0.07
1 month	0.06	0.07
Current year	0.04	0.07
1 year	0.04	0.1
3 years	0.04	0.22
5 years	0.03	0.22
10 years	0.01	0.39

Manager	Title	Age	Since
Edward Pershing CEO	Chief Executive Officer	73	16/04/2024
Eric Wachter CTO	Chief Tech/Sci/R&D Officer	62	15/05/2012
Heather Raines DFI	Director of Finance/CFO	59	25/03/2019

Director	Title	Age	Since
Dominic Rodrigues CHM	Chairman	57	03/04/2017
John Lacey BRD	Director/Board Member	78	27/04/2018
Edward Pershing CHM	Chairman	73	27/04/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-05	Edward Pershing	Fiscal year	Chief Executive Officer	-9,436	0.0022%
05-28	Edward Pershing	Free	Chief Executive Officer	0	0%
05-23	Edward Pershing	Fiscal year	Chief Executive Officer	-32,089	0.0076%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROVECTUS BIOPHARMACEUTICALS, INC.	-11.40%	-3.81%	-20.58%	-48.69%	25.47M
ARGENX SE	+1.03%	+2.30%	+54.92%	+111.78%	56.42B
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+47.26%	+47.26%	44.54B
BIONTECH SE	+1.12%	+2.79%	-13.71%	-17.53%	22.9B
INSMED INCORPORATED	+1.17%	+3.85%	+1.00%	+401.79%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+12.00%	-29.52%	16.4B
GENMAB A/S	+0.15%	+2.24%	+9.10%	-40.04%	15.4B
EXELIXIS, INC.	-0.69%	+0.82%	+27.17%	+178.31%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+14.25%	-	12.36B
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+92.88%	+215.31%	11.15B
Average	+0.48%	+1.50%	+22.43%	+90.96%	21.37B
Weighted average by Cap.	+1.72%	+2.37%	+31.92%	+100.36%

	2024	2025
Net sales	0.62 0.53 0.49 0.46 0.86 58.69 0.88 5.82 2.27 28.55 2.32 2.27 98.86	0.34 0.29 0.27 0.25 0.47 31.96 0.48 3.17 1.23 15.55 1.26 1.23 53.84
Net income	-4.76M -4.12M -3.79M -3.55M -6.66M -453M -6.76M -44.94M -17.49M -220M -17.87M -17.49M -763M	-5.43M -4.7M -4.33M -4.05M -7.6M -516M -7.71M -51.25M -19.94M -251M -20.38M -19.95M -870M
Net Debt	2.88M 2.49M 2.29M 2.15M 4.03M 274M 4.09M 27.15M 10.57M 133M 10.8M 10.57M 461M	2.73M 2.36M 2.17M 2.03M 3.82M 259M 3.87M 25.74M 10.02M 126M 10.24M 10.02M 437M